您当前的位置:
首页 >
文章列表页 >
Clinical evaluation of elderly patients with sarcopenia receiving Shenling baizhu powder combined with nutrition and exercise intervention
更新时间:2025-09-25
    • Clinical evaluation of elderly patients with sarcopenia receiving Shenling baizhu powder combined with nutrition and exercise intervention

    • ZHONGGUO YAOFANG   Vol. 35, Issue 21, Pages: 2652-2657(2024)
    • 作者机构:

      1.华北理工大学附属医院药学部,河北 唐山 063000

      2.华北理工大学附属医院临床营养科,河北 唐山 063000

      3.华北理工大学附属医院呼吸内科,河北 唐山 063000

      4.河北北方学院附属第二医院药剂科,河北 张家口 075000

      5.河北北方学院附属第二医院临床营养科,河北 张家口 075000

    • DOI:10.6039/j.issn.1001-0408.2024.21.13    

      CLC: R969;R956
    • Received:06 February 2024,

      Revised:2024-10-23,

      Accepted:23 October 2024,

      Published:15 November 2024

    移动端阅览

  • JIANG Huanhuan,CHEN Dong,FU Aishuang,et al.Clinical evaluation of elderly patients with sarcopenia receiving Shenling baizhu powder combined with nutrition and exercise intervention[J].ZHONGGUO YAOFANG,2024,35(21):2652-2657. DOI: 10.6039/j.issn.1001-0408.2024.21.13.

  •  
  •  

0

Views

258

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Cost-effectiveness analysis of sacituzumab tirumotecan versus single-agent chemotherapy in second-line and later-line treatment for metastatic triple-negative breast cancer​
Analysis of cost-effectiveness of amivantamab combined with chemotherapy in the treatment of EGFR-mutated advanced non-small cell lung cancer
Cost-effectiveness analysis of gonadotropin-releasing hormone analogue combined with recombinant human growth hormone in the treatment of central precocious puberty
Cost-effectiveness analysis of apatinib combined with adriamycin for second-line treatment of platinum-resistant recurrent ovarian cancer
Cost-effectiveness analysis of tislelizumab combined with chemotherapy as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

Related Author

LIU Guoqiang
GAO Ning
FENG Bing
GAO Shengnan
ZHANG Yuxi
ZHANG Ranran
WANG Xianying
LIANG Miao

Related Institution

Dept. of Clinical Pharmacy, Hebei Medical University Third Hospital
Hebei Society for Integrated Drug and Health Technology Assessment
Dept. of Pharmacy, Hebei Medical University Third Hospital
Dept. of Pharmacy, West China Second Hospital, Sichuan University
Evidence-based Pharmacy Center, West China Second Hospital, Sichuan University
0